Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies
dc.contributor.author | Wang, S. | en |
dc.contributor.author | Mouliere, Florent | en |
dc.contributor.author | Pegtel, D. M. | en |
dc.contributor.author | Chamuleau, M. E. D. | en |
dc.date.accessioned | 2024-10-07T07:25:05Z | |
dc.date.available | 2024-10-07T07:25:05Z | |
dc.date.issued | 2024 | en |
dc.identifier.citation | Wang S, Mouliere F, Pegtel DM, Chamuleau MED. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies. Trends in molecular medicine. 2024 JUL;30(7):660-72. PubMed PMID: WOS:001299001300001. English. | en |
dc.identifier.pmid | 38692937 | en |
dc.identifier.uri | http://hdl.handle.net/10541/627171 | |
dc.description.abstract | Diffuse large B cell lymphoma (DLBCL) exhibits significant biological and clinical heterogeneity that presents challenges for risk stratification and disease surveillance. Existing tools for risk stratification, including the international prognostic index (IPI), tissue molecular analyses, and imaging, have limited accuracy in predicting outcomes. The therapeutic landscape for aggressive lymphoma is rapidly evolving, and there is a pressing need to identify patients at risk of refractory or relapsed (R/R) disease in the context of personalized therapy. Liquid biopsy, a minimally invasive method for cancer signal detection, has been explored to address these challenges. We review advances in liquid biopsy strategies focusing on circulating nucleic acids in DLBCL patients and highlight their clinical potential. We also provide recommendations for biomarkerguided trials to support risk-adapted treatment modalities. | en |
dc.language.iso | en | en |
dc.title | Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies | en |
dc.contributor.department | Cancer Research UK National Biomarker Centre, University of Manchester, Wilmslow Road, Manchester, UK | en |
dc.identifier.journal | Trends In Molecular Medicine | en |
dc.description.note | en] |